| 3.58 0.14 (4.07%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.54 |
1-year : | 5.3 |
| Resists | First : | 3.89 |
Second : | 4.54 |
| Pivot price | 3.3 |
|||
| Supports | First : | 3.38 |
Second : | 3.06 |
| MAs | MA(5) : | 3.36 |
MA(20) : | 3.3  |
| MA(100) : | 4.8 |
MA(250) : | 5.09 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 74.1 |
D(3) : | 56.4 |
| RSI | RSI(14): 52.8 |
|||
| 52-week | High : | 8 | Low : | 2.15 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RLMD ] has closed It is unclear right now based on current values. 52.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.66 - 3.68 | 3.68 - 3.69 |
| Low: | 3.27 - 3.29 | 3.29 - 3.3 |
| Close: | 3.56 - 3.58 | 3.58 - 3.61 |
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Sat, 31 Oct 2026
Relmada Therapeutics, Inc. (RLMD) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada
Tue, 25 Aug 2026
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Tue, 11 Aug 2026
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround - Yahoo Finance
Thu, 06 Aug 2026
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 - Investing News Network
Thu, 06 Aug 2026
Relmada Therapeutics Inc (RLMD) (Q2 2026) Earnings Call Highlights: Strong Phase 2 Data and FDA ... - Yahoo Finance
Fri, 26 Jun 2026
RLMD Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 107 (M) |
| Shares Float | 83 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 94.6 (%) |
| Shares Short | 13,420 (K) |
| Shares Short P.Month | 13,600 (K) |
| EPS | -0.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.94 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.4 % |
| Return on Equity (ttm) | -55.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -46 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -3.94 |
| PEG Ratio | 0 |
| Price to Book value | 1.84 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|